Chang-Ching Shen1, Tsung-Chieh Yao, Kuo-Wei Yeh, Jing-Long Huang. 1. Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital at Linkou, and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Abstract
OBJECTIVES: Patients with juvenile idiopathic arthritis (JIA) have abnormal serum lipid profiles. This study aimed to explore the association of disease activity and anti-rheumatic treatment with serum lipid profiles in a JIA cohort. METHODS: Fifty-eight patients newly diagnosed with JIA who had not been treated with corticosteroids or disease-modifying anti-rheumatic drugs were enrolled. We measured their serum lipid profiles at baseline and 18 months later, and determined whether there were differences in lipid levels and atherogenic indices between patients who were in inactive disease and those who were not. For a case-control comparison at 18 months, control subjects from a population-based study cohort (NAHSIT study) were selected. RESULTS: Thirty-one of the 58 patients achieved inactive disease status after 18-month treatment. In these patients, high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) levels increased significantly (p = 0.001 and p = 0.044); whereas the ratios of low-density lipoprotein cholesterol (LDL-C) to HDL-C and TC to HDL-C decreased with borderline significance (p = 0.066 and p = 0.080). The overall changes in HDL-C levels, LDL-C/HDL-C and TC/HDL-C ratio between baseline and 18 months were correlated with those in C-reactive protein levels (p = 0.005, p = 0.001, and p = 0.002, respectively). There were also significant differences among inactive, active and control subjects in HDL-C and TC levels (p = 0.021 and p = 0.013) but not in LDL, LDL-C/HDL-C, TC/HDL-C ratio, and triglyceride levels. CONCLUSIONS: Abnormal lipid levels and atherogenic indices were associated with disease activity in JIA and improved substantially following effective anti-rheumatic treatment. This improvement may reduce the risk of cardiovascular disease in JIA.
OBJECTIVES:Patients with juvenile idiopathic arthritis (JIA) have abnormal serum lipid profiles. This study aimed to explore the association of disease activity and anti-rheumatic treatment with serum lipid profiles in a JIA cohort. METHODS: Fifty-eight patients newly diagnosed with JIA who had not been treated with corticosteroids or disease-modifying anti-rheumatic drugs were enrolled. We measured their serum lipid profiles at baseline and 18 months later, and determined whether there were differences in lipid levels and atherogenic indices between patients who were in inactive disease and those who were not. For a case-control comparison at 18 months, control subjects from a population-based study cohort (NAHSIT study) were selected. RESULTS: Thirty-one of the 58 patients achieved inactive disease status after 18-month treatment. In these patients, high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) levels increased significantly (p = 0.001 and p = 0.044); whereas the ratios of low-density lipoprotein cholesterol (LDL-C) to HDL-C and TC to HDL-C decreased with borderline significance (p = 0.066 and p = 0.080). The overall changes in HDL-C levels, LDL-C/HDL-C and TC/HDL-C ratio between baseline and 18 months were correlated with those in C-reactive protein levels (p = 0.005, p = 0.001, and p = 0.002, respectively). There were also significant differences among inactive, active and control subjects in HDL-C and TC levels (p = 0.021 and p = 0.013) but not in LDL, LDL-C/HDL-C, TC/HDL-C ratio, and triglyceride levels. CONCLUSIONS: Abnormal lipid levels and atherogenic indices were associated with disease activity in JIA and improved substantially following effective anti-rheumatic treatment. This improvement may reduce the risk of cardiovascular disease in JIA.
Authors: Camila Pugliese; Roberta T A van der Vinne; Lucia M A Campos; Priscila R Guardieiro; Cynthia Saviolli; Eloisa Bonfá; Rosa M R Pereira; Vilma S Viana; Eduardo F Borba; Clovis A Silva Journal: Clin Rheumatol Date: 2015-12-01 Impact factor: 2.980
Authors: Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam Journal: Health Technol Assess Date: 2020-07 Impact factor: 4.014
Authors: Stephanie J W Shoop-Worrall; Suzanne M M Verstappen; Eileen Baildam; Alice Chieng; Joyce Davidson; Helen Foster; Yiannis Ioannou; Flora McErlane; Lucy R Wedderburn; Wendy Thomson; Kimme L Hyrich Journal: Ann Rheum Dis Date: 2017-04-07 Impact factor: 19.103
Authors: Anna-Helene Bohr; Robert C Fuhlbrigge; Freddy Karup Pedersen; Sarah D de Ferranti; Klaus Müller Journal: Pediatr Rheumatol Online J Date: 2016-01-06 Impact factor: 3.054